

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway


Supplementary Materials



Supplementary Figure S1: Metformin increased crizotinib sensitivity in crizotinib-sensitive H3122 cells. (A) Metformin (5 mM) and crizotinib (200 nM) synergistically inhibited the proliferation of H3122 cells, as determined by a Ki67 incorporation assay. *p < 0.01 compared with control; †p < 0.01 compared with the crizotinib treatment alone; †p < 0.01 compared with that of metformin treatment alone. Scale bars, 50 µm; (B) Metformin (5 mM) in combination with crizotinib (200 nM) significantly enhanced the apoptosis of H3122 cells. The images are representative of three independent experiments. *p < 0.01 compared with metformin treatment; (C) Metformin (5 mM) in combination with crizotinib (200 nM) significantly inhibited colony-forming ability of H3122 cells. Cells were cultured for 14 days and then fixed and stained. Colonies with a diameter greater than 1 mm were counted. *p < 0.01 compared with control; †p < 0.01 compared with that of metformin treatment alone; (D) Metformin (5 mM) and crizotinib (200 nM) synergistically inhibited invasiveness of H3122 cells. Scale bars: 100 µm. *p < 0.01 compared with control; †p < 0.01 compared with the crizotinib (200 nM) synergistically inhibited invasiveness of H3122 cells. Scale bars: 100 µm. *p < 0.01 compared with control; †p < 0.01 compared with the crizotinib (200 nM) synergistically inhibited invasiveness of H3122 cells. Scale bars: 100 µm. *p < 0.01 compared with control; †p < 0.01 compared with the crizotinib (200 nM) synergistically inhibited invasiveness of H3122 cells. Scale bars: 100 µm. *p < 0.01 compared with control; †p < 0.01 compared with the crizotinib treatment alone; †p < 0.01 compared with that of metformin treatment alone. Met, metformin; Cri, crizotinib.



Supplementary Figure S2: Metformin alone slightly decreased cell viability. Metformin of 5 mM slightly decreased cell viability in four types of cells used in the current study.



Supplementary Figure S3: Metformin decreased invasion and enhanced apoptosis in H3122-CR cells. (A) Metformin (5 mM) and crizotinib (1 μ M) synergistically inhibited invasiveness of H3122-CR cells. Scale bars: 100 μ m. *p < 0.01 compared with control; †p < 0.01 compared with the crizotinib or metformin treatment alone; (B), Metformin (5 mM) in combination with crizotinib (1 μ M) significantly enhanced the apoptosis of H3122-CR cells. The images are representative of three independent experiments. *p < 0.01 compared with that of control, †p < 0.01 compared with metformin treatment; Met, metformin; Cri, crizotinib.